ViewRay (OTCPK:VRAY.Q) - Aandelenkoers, Nieuws & Analyse

VRAY.Q Overzicht aandelen

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally.

Over het bedrijf

VRAY.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Risicoanalyse

Earnings have declined by 6.6% per year over past 5 years

Does not have a meaningful market cap ($18K)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

ViewRay, Inc. Concurrenten

Motus GI Holdings

OTCPK:MOTS

US$7.2k

ThermoGenesis Holdings

OTCPK:THMO

US$9.5k

Lucira Health

OTCPK:LHDX.Q

US$4.2k

BIOLASE

OTCPK:BIOL.Q

US$256.2k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ViewRay
Historische aandelenkoersen
Huidige aandelenkoers	US$0.0001
52 Week Hoogtepunt	US$4.96
52 Week Laag	US$0.000001
Bèta	0.76
11 maand verandering	-98.88%
3 maanden verandering	-99.57%
1 Jaar Verandering	-100.00%
33 jaar verandering	-100.00%
5 jaar verandering	-100.00%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	VRAY.Q	US Medical Equipment	US Markt
7D	0%	0.2%	-1.6%
1Y	-100.0%	25.8%	30.8%

Rendement versus industrie: VRAY.Q underperformed the US Medical Equipment industry which returned -1.8% over the past year.

Rendement versus markt: VRAY.Q underperformed the US Market which returned 15.2% over the past year.

Prijsvolatiliteit

Is VRAY.Q's price volatile compared to industry and market?
VRAY.Q volatility
VRAY.Q Average Weekly Movement	2,748.1%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: VRAY.Q's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: VRAY.Q's weekly volatility has increased from 1401% to 2748% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	295	Paul Ziegler	www.viewray.com

ViewRay, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ViewRay zich tot de beurswaarde?
VRAY.Q fundamentele statistieken
Marktkapitalisatie	US$18.34k
Inkomsten(TTM)	-US$110.41m
Inkomsten(TTM)	US$105.86m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is VRAY.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VRAY.Q resultatenrekening (TTM)
Inkomsten	US$105.86m
Kosten van inkomsten	US$97.34m
Brutowinst	US$8.52m
Overige uitgaven	US$118.94m
Inkomsten	-US$110.41m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.60
Brutomarge	8.05%
Nettowinstmarge	-104.30%
Schuld/Eigen Vermogen Verhouding	140.7%

Hoe presteerde VRAY.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

VRAY.Q Overzicht aandelen

Beloningen

Risicoanalyse

ViewRay, Inc. Concurrenten

OTCPK:MOTS

US$7.2k

OTCPK:THMO

US$9.5k

OTCPK:LHDX.Q

US$4.2k

OTCPK:BIOL.Q

US$256.2k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company